Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pridopidine dose-finding study in Huntington's disease
NL-OMON44821Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pridopidine in Huntington disease (HD) (5 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change in Unified Huntington's Disease Rating Scale Total Motor Score. Started May 2014; status: active, not recruiting.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON44821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44821.